PF-07321332 Supply Agreement for Pandemic Purposes

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 250,000 units of PF-07321332/ritonavir . It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK's multi-layered approach to COVID-19.